ST. LOUIS, Oct. 26 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. today announced that the Company was recognized in The Wall Street Journal’s second global Technology Innovation Awards for its advanced cardiology instrument control system, Niobe(R).
The awards recognize technological breakthroughs by individuals, companies and organizations around the world in a wide range of areas, including medicine, software, hardware, the Internet, wireless, and broadcasting. Stereotaxis received a Runner-Up distinction in the awards’ Medical Devices category.
The Wall Street Journal received approximately 750 applications from about two-dozen countries. In selecting the winners, Journal editors looked for innovativeness, clarity of explanation and whether the innovation was covered by patents or had achieved some kind of track record.
“Innovation is the key for any company to have continued success, and through these awards The Wall Street Journal recognizes these technological breakthroughs throughout the world,” said Karen Elliott House, publisher of The Wall Street Journal, and senior vice president, Dow Jones & Company. “This year’s winners showed the creative thinking that has allowed them to rise to the top of their respective industries.”
The winners were selected by an independent panel of judges who considered the following factors, among others, in making their selections:
* Innovation should go well beyond what already exists and cannot simply represent incremental improvements. * Innovations need to address major challenges for which new solutions would have a wide-ranging impact in a particular industry. * The application needs to be supported by rigorous data rather than unsubstantiated claims of potential.
“Stereotaxis is honored to receive such a prestigious award from one of the world’s leading business publications,” said Bevil Hogg, Stereotaxis’ President and CEO. “We believe this distinction serves as yet another validation of the unique contributions of our system in the field of cardiology. It is our objective to ensure that the Niobe system becomes a standard of care in interventional medicine, thus creating long-term value for our shareholders.”
About Stereotaxis
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to allow physicians to navigate catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire. Core components of the Stereotaxis System have received regulatory clearance in the U.S. and Europe.
About The Wall Street Journal
The Wall Street Journal, the flagship publication of Dow Jones & Company , is the world’s leading business publication. Founded in 1889, The Wall Street Journal has a print and online circulation of nearly 2.1 million, reaching the nation’s top business and political leaders, as well as investors across the country. Holding 31 Pulitzer Prizes for outstanding journalism, the Journal seeks to help its readers succeed by providing essential and relevant information, presented fairly and accurately, from a dependable and trusted source. The Wall Street Journal print franchise has nearly 600 journalists world-wide, part of the Dow Jones network of nearly 1,800 business and financial news staff. Other publications that are part of The Wall Street Journal franchise, with total circulation of 2.7 million, include The Wall Street Journal Asia, The Wall Street Journal Europe and The Wall Street Journal Online at WSJ.com, the largest paid subscription news site on the Web. In 2005, the Journal was ranked No. 1 in BtoB’s Media Power 50 for the sixth consecutive year.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contacts: Stereotaxis, Inc. Noonan Russo 314-615-6957 212-845-4269 Jim Stolze, Chief Financial Officer Brian Ritchie (investors) jstolze@stereotaxis.combrian.ritchie@eurorscg.com
Stereotaxis, Inc.
CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis, Inc.,+1-314-615-6957, jstolze@stereotaxis.com; or investors - Brian Ritchie ofNoonan Russo, +1-212-845-4269, brian.ritchie@eurorscg.com
